Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: A cohort study

Tropical Medicine and International Health

Volumn 19, Issue 2, 2014, Pages 236-239

  Hoffmann, Christopher J ^a   Charalambous, Salome ^b   Grant, Alison D ^c   Morris, Lynn ^d   Churchyard, Gavin J ^b,c,e   Chaisson, Richard E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AURUM INSTITUTE   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Adherence; Africa; Antiretroviral therapy; Clinical management; HIV; Treatment failure

Indexed keywords

EFAVIRENZ; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

COHORT ANALYSIS; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; PUBLIC HEALTH; RNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT COMPLIANCE; TREATMENT RESPONSE; VIREMIA;

AFRICA;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; HIV; HIV INFECTIONS; HUMANS; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 84892676709     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12237     Document Type: Article

References (19)

1. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI & Wensing AM (2010) Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. The Lancet Infectious Diseases 10, 155-166.
2. Calmy A, Ford N, Hirschel B et al. (2007) HIV viral load monitoring in resource-limited regions: optional or necessary?. Clinical Infectious Diseases 44, 128-134.
3. El-Khatib Z, Delong AK, Katzenstein D et al. (2011) Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. Journal of AIDS & Clinical Research, 2, e1000117.
4. Fox Z, Phillips A, Cohen C et al. (2008) Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 22, 2279-2289.
5. Gallant JE, Rodriguez AE, Weinberg WG et al. (2005) Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. Journal of Infectious Diseases 192, 1921-1930.
6. Guidelines Development Group (2013). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. (eds A Harries & G Hirnschall) World Health Organization, Geneva, Switzerland, pp. 1-269.
7. Gulick RM, Mellors JW, Havlir D et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 337, 734-739.
8. Hoffmann CJ, Charalambous S, Sim J et al. (2009) Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clinical Infectious Diseases 49, 1928-1935.
9. Johnston V, Fielding K, Charalambous S et al. (2012) Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome. PLoS ONE 7, e36997.
10. Marconi VC, Sunpath H, Lu Z et al. (2008) Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clinical Infectious Diseases 46, 1589-1597.
11. McMahon JH, Manoharan A, Wanke CA et al. (2013) Pharmacy and self-report adherence measures to predict virological outcomes for patients on free antiretroviral therapy in Tamil Nadu, India. AIDS and Behavior 17, 2253-2259.
12. Orrell C, Harling G, Lawn SD et al. (2007) Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antiviral Therapy 12, 83-88.
13. Peterson K, Menten J, Peterson I et al. (2013) Use of self-reported adherence and keeping clinic appointments as predictors of viremia in routine hiv care in the Gambia. Journal of the International Association of Providers of AIDS Care. [Epub ahead of print].
14. Pirkle CM, Boileau C, Nguyen VK et al. (2009) Impact of a modified directly administered antiretroviral treatment intervention on virological outcome in HIV-infected patients treated in Burkina Faso and Mali. HIV Medicine 10, 152-156.
15. Rey D, Krebs M, Partisani M et al. (2006) Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes 43, 530-534.
16. Thirumurthy H, Siripong N, Vreeman RC et al. (2012) Differences between self-reported and electronically monitored adherence among patients receiving antiretroviral therapy in a resource-limited setting. AIDS 26, 2399-2403.
17. Wagner GJ & Rabkin JG (2000) Measuring medication adherence: are missed doses reported more accurately then perfect adherence? AIDS Care 12, 405-408.
18. Walmsley S, Bernstein B, King M et al. (2002) Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. New England Journal of Medicine 346, 2039-2046.
19. Wilson D, Keiluhu AK, Kogrum S et al. (2009) HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene 103, 601-606.